pharmaasiaJune 07, 2017
Tag: DSM Sinochem , patent infringement
DSM Sinochem Pharmaceuticals (DSP), the global leader in production and commercialization of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced today that the High Court of Delhi has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical for patent infringement in India.
According to DSM Sinochem Pharmaceuticals’ (DSP) wholly owned subsidiaries, DSM Sinochem Pharmaceuticals Netherlands B.V. and DSM Pharmaceuticals India Pvt. Ltd., the High Court of Delhi, India, has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical Co., LTD ("Weiqida") for patent infringement of Indian Patent Number 247,301. This patent, which is owned by DSP, relates to amoxicillin trihydrate having a low free water content and processes for the manufacture thereof.
The permanent injunction prevents the manufacture, use, importation, offering for sale and sale of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India, as well as any drug product that utilizes the active pharmaceutical ingredient.
"DSP welcomes the Court’s decision," said Karl Rotthier, CEO at DSP. "The lawsuit is intended to protect DSP’s world class intellectual property portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology. DSP will continue to rigorously enforce its IP assets worldwide as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins."
DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: